High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy

Scandinavian Journal of Rheumatology

Volumn 41, Issue 3, 2012, Pages 208-213

  Fritzsche, C ^a   Riebold, D ^a   Munk Hartig, A K ^a   Klammt, S ^a   Neeck, G ^b   Reisinger, E C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b Rostock Clinic South   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE DISEASE; COLLAGEN DISEASE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROBIAL COLONIZATION; NONHUMAN; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SPONDYLOARTHROPATHY; SPUTUM ANALYSIS; VASCULITIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; DNA, FUNGAL; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POLYMERASE CHAIN REACTION; PREVALENCE; RISK FACTORS; SPUTUM; YOUNG ADULT;

EID: 84860572125     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.630328     Document Type: Article

References (31)

1. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20. (Pubitemid 39319360)
2. Saksasithon S, Sungkanuparph S, Thanakitcharu S. Pneumocystis carinii pneumonia in patients without HIV infection. J Med Assoc Thai 2003;86:612-16. (Pubitemid 37151217)
3. Riebold D, Hennig A, Loebermann M, Schareck W, Reisinger EC. Pneumocystis pneumonia in an alcoholic patient with prolonged mechanical ventilation. Eur J Clin Microbiol Infect Dis 2005;24:294-6. (Pubitemid 40768503)
4. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention. BMC Infect Dis 2004;4:42.
5. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002-2004. Scand J Infect Dis 2007;39:589-95. (Pubitemid 47009170)
6. Gerrard JG. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995;162:233-5.
7. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31. (Pubitemid 35013591)
8. Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: A prospective study. Thorax 2003;58:594-7. (Pubitemid 36808130)
9. Gluck T, Geerdes-Fenge HF, Straub RH, Raffenberg M, Lang B, Lode H, et al. Pneumocystis carinii pneumonia as a complication of immunosuppressive therapy. Infection 2000;28:227-30. (Pubitemid 30601421)
10. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009;29:491-6.
11. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000;118:712-20.
12. Chabe M, Dei-Cas E, Creusy C, Fleurisse L, Respaldiza N, Camus D, et al. Immunocompetent hosts as a reservoir of pneumocystis organisms: Histological and rt-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis 2004;23:89-97. (Pubitemid 38392135)
13. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001;39:3877-82. (Pubitemid 33029754)
14. Medrano FJ, Montes-Cano M, Conde M, De la Horra C, Respaldiza N, Gasch A, et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005;11:245-50. (Pubitemid 40239241)
15. Morris A, Kingsley LA, Groner G, Lebedeva IP, Beard CB, Norris KA. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 2004;18:793-8. (Pubitemid 38535008)
16. Helweg-Larsen J, Jensen JS, Dohn B, Benfield TL, Lundgren B. Detection of Pneumocystis DNA in samples from patients suspected of bacterial pneumonia - A case-control study. BMC Infect Dis 2002;2:28.
17. Mori S, Cho I, Ichiyasu H, Sugimoto M. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: A possible association between colonization and development of Pneumocystis jiroveci pneumonia during lowdose MTX therapy. Mod Rheumatol 2008;18:240-6.
18. Savoia D, Millesimo M, Cassetta I, Forno B, Caramello P. Detection of Pneumocystis carinii by DNA amplification in human immunodeficiency virus-positive patients. Diagn Microbiol Infect Dis 1997;29:61-5. (Pubitemid 27502207)
19. Tornatore KM, Venuto RC, Logue G, Davis PJ. CD4+ and CD8+ lymphocyte and cortisol response patterns in elderly and young males after methylprednisolone exposure. J Med 1998; 29:159-83. (Pubitemid 28545446)
20. Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol 2010:125:S195-203.
21. Tabarsi P, Mirsaeidi M, Amiri M, Karimi S, Masjedi MR, Mansouri D. Inappropriate use of steroid and Pneumocystis jiroveci pneumonia: Report of two cases. East Mediterr Health J 2008;14:1217-21.
22. Wissmann G, Morilla R, Martin-Garrido I, Friaza V, Respaldiza N, Povedano J, et al. Pneumocystis jirovecii colonization in patients treated with infliximab. Eur J Clin Invest 2011:41:343-8.
23. Ognibene FP, Shelhamer JH, Hoffman GS, Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: A major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995;151:795-9.
24. Mori S, Imamura F, Kiyofuji C, Ito K, Koga Y, Honda I, et al. Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-Tumor necrosis factor alpha neutralizing antibody. Mod Rheumatol 2006;16:58-62.
25. Kadoya A, Okada J, Iikuni Y, Kondo H. Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996;23:1186-8.
26. Beck JM, Cushion MT. Pneumocystis workshop: 10th anniversary summary. Eukaryot Cell 2009;8:446-60.
27. Harigai M, Koike R, Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007;357:1874-6. (Pubitemid 350044826)
28. Rodriguez LA, Tolosa LB, Ruigomez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care: Incidence and prior morbidity. Scand J Rheumatol 2009;38:173-7.
29. Miguez-Burbano MJ, Ashkin D, Rodriguez A, Duncan R, Pitchenik A, Quintero N, et al. Increased risk of Pneumocystis carinii and community-Acquired pneumonia with tobacco use in HIV disease. Int J Infect Dis 2005;9:208-17. (Pubitemid 40827162)
30. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis 2008;197:10-17. (Pubitemid 351263460)
31. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009;36:1600-5.